Interim report January-March 2016: Good growth in all regions

· Sales amounted to SEK 187 (162) million, corresponding to an increase of 15
percent in SEK. Sales growth was 16 percent in local currency.
  · Operating income before depreciation and amortization (EBITDA) amounted to
SEK 62 (54) million, corresponding to a margin of 33 (33) percent. Operating
income included one-time expenses of SEK 5 million related to the planned
consolidation of the time-lapse business. Adjusted for this, the margin amounted
to 36 percent.
  · Launch of a new range of aspiration needles for oocyte retrieval.
  · Net income amounted to SEK 39 (35) million, which gave earnings per share of
SEK 1.77 (1.61).

Gothenburg, April 26, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
26, 2015 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces
and markets medical devices for assisted reproduction. Work is also carried out
to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/